The invention relates to a compound of formula (I)

##STR00001##

wherein A.sup.1, A.sup.2 and R.sup.1 to R.sup.3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as “biaryl compound”), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as “biaryl compound”), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.

The present disclosure relates generally to chemical compounds and, in some embodiments, to α1A-adrenergic receptor agonists and uses of such agonists in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

Finding a protein of a minute amount present on a cell membrane to provide a method for producing an antibody against the protein. Producing an antibody using a protein identified by an identification method including: a labeling step of using a labeling agent comprising at least one selected from bis-iminobiotin compounds and bis-biotin compounds to obtain cells having a labeled protein; a degradation step of preparing a degradation product for an immobilization treatment, the degradation product containing the labeled protein; an immobilization step of immobilizing the labeled protein contained in the degradation product for an immobilization treatment on a stationary phase via a streptavidin mutant; a cleavage step of releasing an analysis sample from the stationary phase on which the labeled protein is immobilized; and an analysis step of analyzing the analysis sample to identify the labeled protein.

The present application relates to novel 3-imidazolines of formula (I′) and (I) below: (I′) (I) Wherein Ar.sub.1, Ar.sub.2, Ar.sub.3, and R.sub.1 to R.sub.6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics. ##STR00001##

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

The embodiments provide an acidic gas absorbent, an acidic gas removal method using the absorbent, and an acidic gas removal apparatus using the absorbent. The absorbent absorbs an acidic gas in a large amount and is hardly diffused. The acidic gas absorbent according to the embodiment comprises an amine compound represented by the following formula (1): ##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##